J. M. Llovet, L. Villanueva-augusto, F. Anja, and S. Richard, Advances in targeted therapies for hepatocellular carcinoma in the genomic era, Nat Rev Clin Oncol, vol.12, pp.408-424, 2015.

M. H. Attwa and S. A. El-etreby, Guide for diagnosis and treatment of hepatocellular carcinoma, World J Hepatol, vol.7, issue.12, pp.1632-1651, 2015.

M. Sherman, Regorafenib for treatment of hepatocellular carcinoma, Hepatology, vol.67, issue.3, pp.1162-1165, 2018.

X. Ding, Q. Zhu, and S. Zhang, Precision medicine for hepatocellular carcinoma: driver mutations and targeted therapy, Oncotarget, vol.8, issue.33, pp.55715-55730, 2017.

J. Varshosaz and M. Farzan, Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinoma, World J Gastroenterol, vol.21, issue.42, pp.12022-12041, 2015.

B. Renoux, F. Raes, and T. Legigan, Targeting the tumour microenvironment with an enzyme-responsive drug delivery system for the efficient therapy of breast and pancreatic cancers, Chem Sci, vol.8, issue.5, pp.3427-3433, 2017.
URL : https://hal.archives-ouvertes.fr/hal-02174996

X. W. Wang, N. H. Heegaard, and H. Orum, MicroRNAs in liver disease, Gastroenterology, vol.142, issue.7, pp.1431-1443, 2012.

A. Helwak, G. Kudla, T. Dudnakova, and D. Tollervey, Mapping the human miRNA interactome by CLASH reveals frequent noncanonical binding, Cell, vol.153, issue.3, pp.654-665, 2013.

E. Indersie, S. Lesjean, and K. B. Hooks, MicroRNA therapy inhibits hepatoblastoma growth in vivo by targeting beta-catenin and Wnt signaling, Hepatol Commun, vol.1, issue.2, pp.168-183, 2017.

F. Cartier, E. Indersie, and S. Lesjean, New tumor suppressor mi-croRNAs target glypican-3 in human liver cancer, Oncotarget, vol.8, issue.25, pp.41211-41226, 2017.

J. Hayes, P. P. Peruzzi, and S. Lawler, MicroRNAs in cancer: biomarkers, functions and therapy, Trends Mol Med, vol.20, issue.8, pp.460-469, 2014.

Z. Li and T. M. Rana, Therapeutic targeting of microRNAs: current status and future challenges, Nat Rev Drug Discovery, vol.13, issue.8, pp.622-638, 2014.

J. Lam, M. Chow, Y. U. Zhang, and S. Leung, siRNA versus miRNA as therapeutics for gene silencing, Mol Ther Nucleic Acids, vol.4, p.252, 2015.

I. Jeric, G. Maurer, and A. L. Cavallo, A cell-autonomous tumour suppressor role of RAF1 in hepatocarcinogenesis, Nat Commun, vol.7, p.13781, 2016.

S. Giambartolomei, F. Covone, M. Levrero, and C. Balsano, Sustained activation of the Raf/MEK/Erk pathway in response to EGF in stable cell lines expressing the Hepatitis C Virus (HCV) core protein, Oncogene, vol.20, issue.20, pp.2606-2610, 2001.

Z. Wang, L. Ge, M. Wang, and B. I. Carr, Grb2-associated binder-1 plays a central role in the hepatocyte growth factor enhancement of hepatoma growth inhibition by K vitamin analog compound 5, Hepatology, vol.46, issue.6, pp.2003-2013, 2007.

S. Yang and G. Liu, Targeting the Ras/Raf/MEK/ERK pathway in hepatocellular carcinoma, Oncol Lett, vol.13, issue.3, pp.1041-1047, 2017.

K. J. Schmitz, J. Wohlschlaeger, and H. Lang, Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection, J Hepatol, vol.48, issue.1, pp.83-90, 2008.

B. Laloo, D. Simon, and V. Veillat, Analysis of post-transcriptional regulations by a functional, integrated, and quantitative method, Mol Cell Proteomics, vol.8, issue.8, pp.1777-1788, 2009.

M. Maurel, S. Jalvy, and Y. Ladeiro, A functional screening identifies five micrornas controlling glypican-3: role of mir-1271 down-regulation in hepatocellular carcinoma, Hepatology, vol.57, issue.1, pp.195-204, 2013.

E. Henriet, A. Hammoud, A. Dupuy, and J. , Argininosuccinate synthase 1 (ASS1): a marker of unclassified hepatocellular adenoma and high bleeding risk, Hepatology, vol.66, issue.6, pp.2016-2028, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01550711

L. Käll, J. D. Canterbury, J. Weston, W. S. Noble, and M. J. Maccoss, Semi-supervised learning for peptide identification from shotgun proteomics datasets, Nat Methods, vol.4, issue.11, pp.923-925, 2007.

E. W. Deutsch, A. Csordas, and Z. Sun, The ProteomeXchange consortium in 2017: supporting the cultural change in proteomics public data deposition, Nucleic Acids Res, vol.45, issue.D1, pp.1100-1106, 2017.

V. Agarwal, G. W. Bell, J. Nam, and D. P. Bartel, Predicting effective mi-croRNA target sites in mammalian mRNAs, Elife, vol.4, p.5005, 2015.

H. Dweep, N. Gretz, and . Mirwalk2, 0: a comprehensive atlas of mi-croRNA-target interactions, Nat Methods, vol.12, issue.8, pp.697-697, 2015.

Y. H. Hwang, J. Y. Choi, and S. Kim, Over-expression of c-raf-1 protooncogene in liver cirrhosis and hepatocellular carcinoma, Hepatol Res, vol.29, issue.2, pp.113-121, 2004.

S. Boyault, D. S. Rickman, and A. De-reyniès, Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets, Hepatology, vol.45, issue.1, pp.42-52, 2007.
URL : https://hal.archives-ouvertes.fr/inserm-00130313

E. Indersie, K. B. Hooks, and C. Capdevielle, Tracking cellular and molecular changes in a species-specific manner during experimental tumor progression in vivo, Oncotarget, vol.9, issue.22, pp.16149-16162, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01724071

L. Chen, L. Yuan, and G. Wang, Identification and bioinformatics analysis of miRNAs associated with human muscle invasive bladder cancer, Mol Med Rep, vol.16, issue.6, pp.8709-8720, 2017.

A. I. Hironaka-mitsuhashi, J. Matsuzaki, and R. Takahashi, A tissue microRNA signature that predicts the prognosis of breast cancer in young women, PLoS ONE, vol.12, issue.11, p.187638, 2017.

X. Wu, X. Xu, and S. Li, Identification and validation of potential biomarkers for the detection of dysregulated microRNA by qPCR in patients with colorectal adenocarcinoma, PLoS ONE, vol.10, issue.3, p.120024, 2015.

Q. Zhang, E. Spears, D. N. Boone, Z. Li, M. A. Gregory et al., Domainspecific c-Myc ubiquitylation controls c-Myc transcriptional and apoptotic activity, Proc Natl Acad Sci, vol.110, issue.3, pp.978-983, 2013.

A. Czubaty and A. Piekielko-witkowska, Protein kinases that phosphorylate splicing factors: roles in cancer development, progression and possible therapeutic options, Int J Biochem Cell Biol, vol.91, pp.102-115, 2017.

J. Shen, Z. Xiao, and W. Wu, Epigenetic silencing of miR-490-3p reactivates the chromatin remodeler SMARCD1 to promote Helicobacter pylori-induced gastric carcinogenesis, Cancer Res, vol.75, issue.4, pp.754-765, 2015.

C. Inoue, C. Zhao, and Y. Tsuduki, SMARCD1 regulates senescenceassociated lipid accumulation in hepatocytes, NPJ Aging Mech Dis, vol.3, p.11, 2017.

K. B. Hooks, J. Audoux, and H. Fazli, New insights into diagnosis and therapeutic options for proliferative hepatoblastoma, Hepatology, vol.68, issue.1, pp.89-102, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01677306

D. T. Leicht, V. Balan, and J. Zhu, MEK-1 activates C-Raf through a Ras-independent mechanism, Biochim Biophys Acta, vol.1833, issue.5, pp.976-986, 2013.

Z. Karoulia, E. Gavathiotis, and P. I. Poulikakos, New perspectives for targeting RAF kinase in human cancer, Nat Rev Cancer, vol.17, issue.11, pp.676-691, 2017.

F. Wang, C. Jiang, and Q. Sun, miR-195 is a key regulator of Raf1 in thyroid cancer, Onco Targets Ther, vol.8, pp.3021-3028, 2015.

Z. Liu, Y. Liu, and L. Li, MiR-7-5p is frequently downregulated in glioblastoma microvasculature and inhibits vascular endothelial cell proliferation by targeting RAF1, Tumour Biol, vol.35, issue.10, pp.10177-10184, 2014.

L. Chen, Y. Shi, C. Jiang, L. Wei, Y. Wang et al., Expression and prognostic role of pan-Ras, Raf-1, pMEK1 and pERK1/2 in patients with hepatocellular carcinoma, Eur J Surg Oncol, vol.37, issue.6, pp.513-520, 2011.

A. Ghousein, N. Mosca, and F. Cartier, miR-4510 blocks hepatocellular carcinoma development through RAF1 targeting and RAS/RAF/MEK/ERK signalling inactivation, Liver Int, vol.00, pp.1-12, 2019.
URL : https://hal.archives-ouvertes.fr/inserm-02437915